These findings validate the selectivity of bindarit in inhibiting MCP-1 and demonstrate that MCP-1, though not exclusively, has a paramount role in melanoma and astrocyte interaction, facilitating tumor cell aggressiveness. The gene discussed is CCL2; the disease is neoplasm.